Nuevocor, a pre-clinical stage biotechnology company, announced on Thursday that it has named Dr John Lee, MD, PhD, as its new chief Medical officer.
Dr Lee, a life science executive, has more than 15 years of clinical development and regulatory experience from early drug discovery to late-stage clinical development. He has most recently served as the chief medical officer of PhaseBio Pharmaceuticals. He has served as vice president, global head, Cardiovascular Center of Excellence at Quintiles and executive director, Discovery Medicine at Bristol-Myers Squibb, and has served in leadership roles in both biotech and pharmaceutical sectors.
Dr Yann Chong Tan, PhD, CEO and co-founder of Nuevocor, said, 'Dr Lee's appointment marks a significant milestone for Nuevocor. His extensive experience and proven track record in clinical development make him the ideal candidate to lead our clinical development team. His leadership will be instrumental in furthering our commitment to advancing science and translating it into therapies that will make a real difference in patients' lives.'
AstraZeneca completes acquisition of Amolyt Pharma
CureLab Oncology names new CMO
Tempus announces receipt of FDA clearance for AI-based AFib risk detection
Revelation Biosciences' Phase 1 study shows promising results for TLR4 agonist Gemini
Smartcella adds new board members
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Haemonetics' TEG 6s hemostasis cartridge gains FDA clearance
Polymedco's PATHFAST hs-cTnI-II test receives US FDA clearance
Gilgamesh Pharmaceuticals receives multi-year USD14m grant from NIDA
Advanced Medical Solutions Group plc proposes GBP120.8m acquisition of Peters Surgical
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes